Onyx Biotec Ltd. is a pharmaceutical company engaged in the manufacture, sale, and distribution of generic and proprietary pharmaceutical products. It develops, manufactures and distributes generic and branded pharmaceutical products in various forms, like water for injection (WFI), dry powder injections, and dry powder syrup. WFI is a sterile preparation of water, which is supplied only in single-dose containers, indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection. Its dry powder injections include Ceftriaxone and Sulbactam for Injection, Cefazoline Sodium for Injection, and Cefepime and Tazobactam for Injection, among others. Its dry powder syrups include Cefpodoxime Proxetil, Cefuroxime Axetil, and others. Its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Its services also include preparation and filing of regulatory dossiers in the Indian and global markets.As of 25 May 2026, ONYX BIOTEC LIMITED share price is ₹29.80. The stock opened at ₹29.80, compared to its previous close of ₹29.80. During today's trading session, ONYX BIOTEC LIMITED share price moved in the range of ₹29.80 to ₹29.80, with an average price of ₹29.80 for the day. Looking at its last 52-week, the stock has touched a low of ₹29.80 and a high of ₹29.80. On the performance front, ONYX BIOTEC LIMITED share price has declined by 20.53% over the last six months and is down 39.80% on a year-on-year basis.
The market capitalization of ONYX BIOTEC LIMITED is ₹54 Crs, with a P/E ratio of -248.3 and a dividend yield of 0.00%.